Christopher M. Gomez to Myasthenic Syndromes, Congenital
This is a "connection" page, showing publications Christopher M. Gomez has written about Myasthenic Syndromes, Congenital.
Connection Strength
2.537
-
Selective inhibition of caspases in skeletal muscle reverses the apoptotic synaptic degeneration in slow-channel myasthenic syndrome. Hum Mol Genet. 2014 Jan 01; 23(1):69-77.
Score: 0.442
-
Skeletal muscle IP3R1 receptors amplify physiological and pathological synaptic calcium signals. J Neurosci. 2011 Oct 26; 31(43):15269-83.
Score: 0.390
-
Calpain activation impairs neuromuscular transmission in a mouse model of the slow-channel myasthenic syndrome. J Clin Invest. 2007 Oct; 117(10):2903-12.
Score: 0.294
-
Inositol-1,4,5-triphosphate receptors mediate activity-induced synaptic Ca2+ signals in muscle fibers and Ca2+ overload in slow-channel syndrome. Cell Calcium. 2007 Apr; 41(4):343-52.
Score: 0.274
-
Activation of apoptotic pathways at muscle fiber synapses is circumscribed and reversible in a slow-channel syndrome model. Neurobiol Dis. 2006 Aug; 23(2):462-70.
Score: 0.270
-
Focal caspase activation underlies the endplate myopathy in slow-channel syndrome. Ann Neurol. 2004 Mar; 55(3):347-52.
Score: 0.229
-
Active calcium accumulation underlies severe weakness in a panel of mice with slow-channel syndrome. J Neurosci. 2002 Aug 01; 22(15):6447-57.
Score: 0.206
-
Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms. Ann Neurol. 2002 Jan; 51(1):102-12.
Score: 0.198
-
Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome. Exp Neurol. 2015 Aug; 270:88-94.
Score: 0.120
-
Novel beta subunit mutation causes a slow-channel syndrome by enhancing activation and decreasing the rate of agonist dissociation. Mol Cell Neurosci. 2006 May-Jun; 32(1-2):82-90.
Score: 0.067
-
Presynaptic congenital myasthenic syndrome due to quantal release deficiency. Neurology. 2001 Jul 24; 57(2):279-89.
Score: 0.048